Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Modine Manufacturing Company (MOD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Modine Manufacturing CompanyTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Modine Manufacturing Company vs Neurocrine Biosciences Inc — how do they compare? Modine Manufacturing Company trades at $184.56 (market cap $10.06B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Modine Manufacturing Company is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Neurocrine Biosciences Inc for 23 Days on average.

MODNBIX
Market Cap
$10.06B$14.60B
Volume
1,340,6051,075,694
Sector
IndustrialsHealth
52-Week High
$283.95$185.50
52-Week Low
$110.73$123.10
Typical Hold Time
33 Days23 Days
Enterprise Value
$10.49B$14.61B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Modine Manufacturing Company

Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.

The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.

The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MOD
100% Buy0% Sell
Avg holding period · 33 Days
NBIX

No sentiment data available yet.

Top news

Latest headlines on both assets

About Modine Manufacturing Company

Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.

Read more on MOD →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX →